VIENNAâ€”For women with premenopausal breast cancer the benefits of using the most adjuvant endocrine treatment needs to be weighed against additional side effectsâ€”according to Marco Colleoni MD from the European Institute of Oncology in Milan. After his talk at the St Gallen breast cancer conference he discussed criteria for individualizing optimal endocrine adjuvant treatments with Oncology Times reporter Sarah Maxwell.
You may also like...
Oncology Times Broadcast News with the Audio Journal of Oncology 11 Nov, 2008 ASCO Annual Meeting Daily News Podcasts – June 4th, 2007 5 Jun, 2007 Clear-cell renal cell cancer: first molecular prognostic marker also brings scope for drug targeting 27 Feb, 2014 No Prime Time Soon for Vaccines in Lung Cancerâ€”Immune Suppression Reversal Urgently Needed 20 Apr, 2015
- Previous story Genetic Tests for Breast Cancer Late Recurrence Riskâ€”Not Yet Ready for Prime Time
- Next story Deep Genomic Profiling in Breast Cancer Promises to Improve Outcomes
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014